The Research Triangle Park, N.C.-based company posted losses of $20.2 million, or 10¢ per share, on sales of $5.4 million for the three months ended September 30, seeing losses shrink 47.5% while sales grew nearly 3000% compared with the same period during the previous year
Adjusted to exclude one-time items, losses per share were 6¢, just ahead of the 7¢ loss-per-share consensus on Wall Street where analysts expected to see sales of $5.3 million, which TransEnterix topped.
“We are proud of the progress we made during the third quarter, as we continued to drive adoption of the Senhance System by executing on our sales and marketing strategy and continuing to develop the capabilities of the Senhance System to deliver on our vision of digital laparoscopy. We are focused on driving the global adoption of the Senhance System by increasing the applicability of the system for a wider range of surgeons, patients and geographies,” prez & CEO Todd Pope said in a press release.
Shares in TransEnterix did not move in trading today, closing at $3.39.
Earlier this month, TransEnterix completed its acquisition of Medical Surgery Technologies.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.